The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRO-XL: A phase II study of zanzalintinib (XL092) in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on lutetium-177 (177Lu)-PSMA-617.
 
Umang Swami
Consulting or Advisory Role - Adaptimmune; Astellas Pharma; AstraZeneca; Exelixis; Gilead Sciences; Imvax; Janssen Scientific Affairs; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); lava therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst)
 
Kenneth Boucher
No Relationships to Disclose
 
Yeonjung Jo
No Relationships to Disclose
 
Colin Moynier
No Relationships to Disclose
 
Susan Clement
No Relationships to Disclose
 
Tenzin Phunrab
No Relationships to Disclose
 
Julia Batten
No Relationships to Disclose
 
Joshua Quertinmont
No Relationships to Disclose
 
Jon Mahlow
No Relationships to Disclose
 
Vinay Mathew Thomas
No Relationships to Disclose
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Acrotech Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Viralytics (Inst)
(OPTIONAL) Uncompensated Relationships - Astellas Pharma
 
Manish Kohli
Employment - nference (I)
Stock and Other Ownership Interests - Atzeyo Biosensors; Cancer Healing Networks
Honoraria - Advanced Accelerator Applications
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Cytogen; Genapsys; Tempus
Patents, Royalties, Other Intellectual Property - Patent number: 10982286. Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
Travel, Accommodations, Expenses - Celgene; Olink Proteomics INC
 
Benjamin Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Lilly; Merck; Peloton Therapeutics; Pfizer; Sanofi; Telix Pharmaceuticals; Tempus; Xencor
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer